Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Consolidates RNA, Proteomics, Reagents Businesses

NEW YORK, March 5 (GenomeWeb News) - Agilent Technologies has consolidated into a single corporate division its gene-expression, proteomics, and reagents businesses, the company said today.

 

The newly formed Integrated Biology Solutions unit will reside within Agilent's Life Sciences and Chemical Analysis business group. Fran DiNuzzo, vice president of the bio-reagents, consumables, and services, will oversee the new division, Agilent said.
 
The unit, modeled on the systems biology approach, will "provide a single interface through which Agilent can better serve its customers in basic research, drug discovery and early-stage drug development," said DiNuzzo, whose new title is vice president and general manager of IBS. He also said the division will "enable" Agilent to better develop new products "that bridge multiple disciplines."

 

Christina Maehr, a spokeswoman for Agilent, told GenomeWeb News that the company has no current plans to eliminate any positions. "This move is not an attempt to cut back" on spending, she said. Additionally, she said the company is "hiring for several positions," including industry marketing manager.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.